Research graph
References from The Impact of SF3B1 Mutations on the Tumor Microenvironment and Response to Immunotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
The Clinical Role of the TME in Solid Cancer
10.1038/s41416-018-0327-z · 2019 · External reference
Cancer Genome and Tumor Microenvironment: Reciprocal Crosstalk Shapes Lung Cancer Plasticity
10.7554/elife.79895 · 2022 · External reference
The Evolving Landscape of Biomarkers for Checkpoint Inhibitor Immunotherapy
10.1038/s41568-019-0116-x · 2019 · External reference
Anti‐PD‐1 and Anti‐CTLA‐4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
10.3389/fonc.2018.00086 · 2018 · External reference
PD‐1/PD‐L1 Inhibitors
10.1016/j.coph.2015.05.011 · 2015 · External reference
Systemic Immunity in Cancer
10.1038/s41568-021-00347-z · 2021 · External reference
Melanoma‐Intrinsic Beta‐Catenin Signalling Prevents Anti‐Tumour Immunity
10.1038/nature14404 · 2015 · External reference
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
10.1158/2159-8290.cd-17-1327 · 2018 · External reference
Genomic and Transcriptomic Features of Response to Anti‐PD‐1 Therapy in Metastatic Melanoma
10.1016/j.cell.2016.02.065 · 2016 · External reference
A Chemical Genetics Approach for the Functional Assessment of Novel Cancer Genes
10.1158/0008-5472.can-14-2930 · 2015 · External reference
Spliceosomal Disruption of the Non‐Canonical BAF Complex in Cancer
10.1038/s41586-019-1646-9 · 2019 · External reference
Functional and Conformational Impact of Cancer‐Associated SF3B1 Mutations Depends on the Position and the Charge of Amino Acid Substitution
10.1016/j.csbj.2021.02.012 · 2021 · External reference
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
10.1016/j.cell.2018.09.006 · 2018 · External reference
Integrative Genomics Analysis Reveals the Multilevel Dysregulation and Oncogenic Characteristics of TEAD4 in Gastric Cancer
10.1093/carcin/bgt409 · 2014 · External reference
Epigenetic Silencing of miR‐1271 Enhances MEK1 and TEAD4 Expression in Gastric Cancer
10.1002/cam4.1605 · 2018 · External reference
The Need for Multi‐Omics Biomarker Signatures in Precision Medicine
10.3390/ijms20194781 · 2019 · External reference
Immuno‐Oncology Drug Development Goes Global
10.1038/d41573-019-00167-9 · 2019 · External reference
A Guide for Bioinformaticians: Omics‐Based Drug Discovery for Precision Oncology
10.1016/j.drudis.2020.08.004 · 2020 · External reference
The Immune Landscape of Cancer
10.1016/j.immuni.2018.03.023 · 2018 · External reference
IFN‐Gamma‐Related mRNA Profile Predicts Clinical Response to PD‐1 Blockade
10.1172/jci91190 · 2017 · External reference
Tumor Plasticity and Resistance to Immunotherapy
10.1016/j.trecan.2020.02.001 · 2020 · External reference
Regulatory T Cells in Cancer Immunotherapy
10.1038/cr.2016.151 · 2017 · External reference
Axl Inhibition Induces the Antitumor Immune Response Which Can Be Further Potentiated by PD‐1 Blockade in the Mouse Cancer Models
10.18632/oncotarget.21125 · 2017 · External reference
Molecular Pathways: Oncologic Pathways and Their Role in T‐Cell Exclusion and Immune Evasion‐A New Role for the AXL Receptor Tyrosine Kinase
10.1158/1078-0432.ccr-17-0189 · 2017 · External reference
Cancer‐Associated Fibroblasts and Their Influence on Tumor Immunity and Immunotherapy
10.7554/elife.57243 · 2020 · External reference
Successes and Failures: What Did We Learn From Recent First‐Line Treatment Immunotherapy Trials in Non‐Small Cell Lung Cancer?
10.1186/s12916-017-0819-3 · 2017 · External reference
Tumor Mutational Load Predicts Survival After Immunotherapy Across Multiple Cancer Types
10.1038/s41588-018-0312-8 · 2019 · External reference
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
10.1158/2326-6066.cir-16-0114 · 2017 · External reference
Intratumoral T‐Cell Infiltrates and MHC Class I Expression in Patients With Stage IV Melanoma
10.1158/0008-5472.can-04-4621 · 2005 · External reference
Mechanisms Regulating T‐Cell Infiltration and Activity in Solid Tumors
10.1093/annonc/mdx238 · 2017 · External reference
Chemokine Expression in Melanoma Metastases Associated With CD8+ T‐Cell Recruitment
10.1158/0008-5472.can-08-2281 · 2009 · External reference
Interleukin 10 in the Tumor Microenvironment: A Target for Anticancer Immunotherapy
10.1007/s12026-011-8262-6 · 2011 · External reference
Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis Through MYC Stabilization
10.1158/2159-8290.cd-19-1330 · 2020 · External reference
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma
10.1016/j.ccell.2017.07.003 · 2017 · External reference
SF3B1 Mutations in Chronic Lymphocytic Leukemia
10.1182/blood-2013-02-427641 · 2013 · External reference
Splicing Patterns in SF3B1‐Mutated Uveal Melanoma Generate Shared Immunogenic Tumor‐Specific Neoepitopes
10.1158/2159-8290.cd-20-0555 · 2021 · External reference
Characterization of Genetics in Patients With Mucosal Melanoma Treated With Immune Checkpoint Blockade
10.1002/cam4.3789 · 2021 · External reference
Cancer‐Associated SF3B1 Mutations Affect Alternative Splicing by Promoting Alternative Branchpoint Usage
10.1038/ncomms10615 · 2016 · External reference
Current Treatment of Uveal Melanoma
10.3390/cancers17091403 · 2025 · External reference
Mutational Landscape of the Transcriptome Offers Putative Targets for Immunotherapy of Myeloproliferative Neoplasms
10.1182/blood.2019000519 · 2019 · External reference
